Dry Eye Clinical Trial
Official title:
Randomised Research Comparing Acupuncture, Herbal Treatment and Artificial Tear Eye Drops in Dry Eye
Dry eye is a major, common medical condition with significant health and economic burden in
Singapore and worldwide. It is a holistic problem affected by living habits, nutrition and
underlying systemic disease, inducing a significant decrease in quality-of-life. The
hallmark of this disease is raised tear osmolarity and inflammation. There is no definitive
cure for this condition, as treatment in the form of lubricants is only symptomatic and
treatment with cyclosporine eyedrops is expensive and may not be well tolerated.
Following the rise in international interest in complementary medicine,
randomized-controlled studies in dry eye using Traditional Chinese Medicine (TCM) have been
published, with mixed results. However, the major limitation of these studies is the lack of
objective assessment for inflammation.
We propose to collaborate with an academically-trained Singapore TCM physician who has
conducted dry eye trials, and synergistically exploit the existing state-of-the-art dry eye
monitoring technologies available at Singapore Eye Research Institute (SERI). This proposal
is cost-effective, building on previous government grants and expertise to provide
definitive scientific evidence on the efficacy and safety of TCM in dry eye. SERI has an
international reputation for interventional studies, and the PI has a good academic
relationship with the above TCM physician. We propose to screen, recruit and treat 150
patients with a herbal preparation and acupuncture, and evaluate over 4 weeks in a
randomized-controlled study. Tests to be performed will include tear imaging and osmolarity,
as well as protein and cytokine assays.
Singapore is uniquely positioned at the crossroads of the East and the West to take the lead
in this field. Given that there is an increasing patient interest in holistic care in
Singapore and the rise of scientifically trained TCM practitioners, a study like this one is
very timely, and will have tremendous impact to healthcare delivery in Singapore.
Dry eye is a major, common medical condition with significant health burden in Singapore and
worldwide. As much as one third of the adult population in Asian countries are affected by
dry eye. It has been shown that dry eye affects quality of life, including the performing of
daily activities such as reading and driving a car. Moderate severity of dry eye affects
some patients like moderate angina. The direct and indirect cost of treating dry eye is high
and increasing. For example, it costs individuals about US$800 per year to treat dry eye,
but the cost to society for managing such a patient is US$12000 per year. (1-29)
Dry eye is a holistic problem affected by living habits such as working long hours on the
computer and in a dry, air-conditioned environment. It is also associated with poor
nutrition and intake of dietary supplements such as omega-3 and omega-6 fatty acids may help
to treat dry eye. Dry eye is also a systemic immune mediated disease, and aggravated by
those with autoimmune Sjögren's syndrome, rheumatoid arthritis, thyroid disease, systemic
lupus erythematosis, Steven Johnson syndrome and chronic graft versus host disease.
In a recent international workshop, international experts in dry eye agree that the hallmark
of this disease is raised tear osmolarity and ocular surface inflammation. Traditionally,
dry eye is diagnosed by a reduced Schirmer's test and/or reduced tear break up time or the
presence of dry eye symptoms. In addition to these traditional tests, it would be
advantageous to incorporate measurements of osmolarity and inflammation in clinical studies.
There is no definitive cure for this condition, as treatment in the form of lubricants is
only symptomatic and treatment with cyclosporine eye drops is expensive and may not be well
tolerated. Treatment with steroids can be effective but associated with adverse effects such
as sight threatening glaucoma. In summary there is a definite medical need for alternative
therapies in dry eye.
Traditional Chinese Medicine (TCM) is involved in restoring the natural balance of the body,
which results in disease like dry eye when this is disturbed. In TCM philosophy, dry eye may
result from syndromes such as yin deficiency in the liver or kidney. Modalities such as
acupuncture or herbs can be used judiciously to restore the balance in specific patients.
Recently there have been randomized controlled studies in dry eye using acupuncture and
herbs, with mixed results, refer to attachment (Table 1). The major limitation of these
studies is that objective tear film evaluation such as tear osmolarity, and tear cytokines
and proteins, which are indicative of ocular surface inflammation, have not been evaluated.
In addition, some studies suffer from lack of proper controls or randomization.
If the mainstream practitioners of evidence based medicine are convinced that TCM can
fundamentally alter the pathological processes in dry eye, they will be more receptive to
this form of treatment. At the same time, regulatory bodies need to be reassured that TCM is
safe in dry eye, so that more education and promotion of such treatment can benefit more
people.
The PI runs a dry eye clinic twice a week at the Singapore National Eye Centre since 2006.
He is aware that many dry eye patients in Singapore have experienced a host of more
conventional therapies and are eager to attempt alternative forms of therapy. This trend
towards TCM and holistic medicine will continue regardless of the attitudes of 'western'
medical practitioners. This study, when completed, will present an opportunity for bridging
the gaps between the two health care communities who do not normally interact. Since latest
scientific tools in terms of protein science and imaging will be employed in the study, it
will definitely increase the evidence based medicine for TCM in the dry eye field.
The PI has published 67 peer reviewed papers in dry eyes and related ocular surface
processes, including review articles,(30-34) international expert panel report,(35)
epidemiological studies,(36-37) PI initiated and industry sponsored interventional drugs
including randomized controlled drug trials.(38-40) In one pharmacy in Singapore alone, the
cost of dry eye medications amounted to US$1.5 million in one year.(3) He has also found in
an epidemiological study in Singapore people that dry eye impairs visual associated function
related activities of daily living.(41) He established the only dedicated dry eye service in
the region and has produced many papers relating to the assessment of these patients,(42-46)
including one that found dry eye being related to the amount exposure to stressful
activities and conditions.(46) The PI has experience in the biochemical evaluation of
patient tears and materials in dry eye(47-51) and clinical imaging related to dry
eye.(52-54) Lastly, he has also appeared in mass media educational articles including press
releases and articles/talks for layperson and general practitioners.
A survey was conducted among registered TCM practitioners in Singapore and published in a
peer reviewed journal.(55) This showed that a significant proportion of these institutional
practitioners are keen to practice in dry eye. This study was also chosen to be presented as
an oral presentation at the 10th Asean Congress of TCM cum 3rd Asia Advanced Forum on
Acupuncture and Moxibustion. At the same time, the full article has been translated into
Chinese in the congress proceedings page 192-197 to appeal to the audience of TCM
physicians. The PI has also participated in discussion on data analysis in TCM trials.
(56-57) In addition, acupuncture in rabbits had shown to induce changed in tear proteins,
although this has not been evaluated in humans. (58)
1. HYPOTHESIS AND OBJECTIVES
The overall hypothesis is that traditional Chinese medicine modalities of acupuncture
and herbs can improve the symptoms and signs of dry eye, and objectively, these
improvements are associated with reduction of tear osmolarity and reduction of
inflammatory markers such as tear cytokines and proinflammatory proteins. There is also
a long term objective of integrating TCM and mainstream medical care and having a
cost-effective approach to eye disease.
Primary outcome:
• Change in SPEED score (Week4-Week0)
Secondary outcomes:
- Change in Tear Evaporimetry
- Change in TCM score (Lung-Kidney Yin deficiency)
- Change in NIBUT
- Change in Schirmers I
- Change in Corneal fluorescein staining (5 zones)
- Change in Tear osmolarity
- Change in Tear meniscus height
- Change in Tear protein/ cytokine levels
1.1 Primary Objectives
We aim to show that dry eye patients treated with acupuncture is efficacious (can
improve symptoms and signs of dry eye) and safe (no ocular and systemic side effects).
1.2 Secondary Objectives
We aim to show that dry eye patients treated with a herbal preparation is efficacious
(can result in reduction of symptoms and signs of dry eye) and safe (no ocular and
systemic side effects).
We also aim to show that objective, definitive hallmarks of dry eye disease, ie. Tear
osmolarity and surrogates of ocular surface inflammation, such as tear cytokines and
proinflammatory proteins, are reduced after treatment by acupuncture and herbal
treatment, compared to control.
1.3 Potential Risks and Benefits: 1.3.1 Potential Risks We will anticipate minimal risk
and discomfort involve in this study.
- It is possible that eyelid bruising and swelling may occur from acupuncture
needles
- Some slight discomfort from Schirmers I test
- Nausea, insomnia, headache, loss of appetite, malaise, diarrhoea and abdominal
cramps may occur after herbal consumption
Relatively few complications have been reported from the use of acupuncture. However,
acupuncture can cause potentially serious side effects if not delivered properly by a
qualified practitioner. The most common side effects after acupuncture include
soreness, bruises, fatigue, lightheadedness and involuntary twitching of muscle. Should
this event occur, increased frequency of visits to the eye clinic may be necessary.
1.3.2 Potential Benefits There is no assurance participants will benefit from this
study. However, their participation may contribute to the medical knowledge whether TCM
medicine can fundamentally alter the pathological processes in dry eye. At the same
time, regulatory bodies need to be reassured that TCM is safe in dry eye, so that more
education and promotion of such treatment can benefit more people.
2. STUDY POPULATION 3.1 List The Number and Nature of Subjects to be Enrolled. One hundred
and fifty eligible dry eye subjects will be screened and recruited from SCHMI.
3.2 Criteria for Recruitment and Recruitment Process
1. Subjects meet all the inclusion criteria listed below.
2. Clear of exclusion criteria.
Permission would be sought from the attending TCM physicians before subjects are being
recruited. Eligible subjects will be counselled on the study. If subject is interested,
informed written consent will be obtained from all participants. Thereafter, optometrsits at
SCHMI will schedule a baseline visit to SERI for ocular monitoring.
3.3 Inclusion Criteria
For eligibility each participant presenting at SCHMI must be assessed by the TCM physician
and optometrist, and found to satisfy every one of the following:
1. Age: 40-85 years, visual acuity better than logMAR of 1.0
2. Chief complaint should be dry eye
3. Symptoms:
3.1. SPEED score > 6 3.2. TCM score satisfies lung-kidney yin deficiency profile
4. Signs:
4.1. TBUT (<10s) or Schirmer's test (<10mm/5 mins) 4.2 Any corneal fluorescein staining
3.4 Exclusion Criteria All subjects meeting any of the exclusion criteria at screening visit
will be excluded from participation.
1. Glaucoma or other ophthalmic disease, eg. Extraocular muscle palsies, ectropion,
entropion
2. Ocular allergies, eg. Allergic conjunctivitis, sinusitis, eczema, atopic
keratoconjuntivitis
3. Known of thyroid disorders (diagnosed by physician)
4. Trichiasis
5. Eye surgeries patients including LASIK (within 1 year)
6. Steven-Johnson syndrome
7. Sjogren's syndrome
8. Eye related trauma (within 1 year)
9. Contact lens wear (within 1 year)
10. Punctal occlusion
11. Systemic disease requiring regular medication (except hypertension and lipidemia)
12. Pregnancy or planning to be pregnant
13. Requirement for medications such as anti-microbial, inflammatory, creams (except
moisturizers or cosmetics), or steroidal therapies
14. Unable to do this clinical trial for any reason
4 STUDY DESIGN This is a randomized observer masked parallel group three arm interventional
study.
Treatment arms
There will be 3 trial arms in this study:
- Control: Systane Ultra Eye drop (n=50)
- Systane Ultra Eye Drop and Acupuncture treatment (n=50)
- Systane Ultra Eye Drop and Herbs treatment (n=50)
Study duration: 5 Weeks Recruitment duration: 1 Year
4.1 Randomisation and Blinding
The randomisation procedure used will entail:
1. Presence of two witnesses
2. Drawing of lots
3. Randomization codes for the 3 groups will be noted. For e.g. 001A, 002B, 003C etc.
4. Study information related to randomisation will be filed and kept at SCHMI
5. Only unblinded personnel have access to the randomization code file
Randomisation will be done at SCHMI. Study members at SCHMI will be unblinded as they will
be delivering TCM treatments to the subjects. However, study members at SERI will all be
blinded so as to prevent unintentional biases when assessing and monitoring of ocular
surface.
In a situation of a serious event, a decision on whether to open (break) the code for the
specific patient is necessary. Although it is advantageous to retain the blind for all
patients prior to final study analysis, when a serious adverse reaction is judged reportable
on an expedited basis, it is recommended that the blind be broken only for that specific
patient by the designated investigator who is unblind. It is also recommended that, when
possible and appropriate, the blind be maintained for those persons, such as biometrics
personnel, responsible for analysis and interpretation of results at the study's conclusion.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05027087 -
The Effect of a Novel Blueberry Supplement on Dry Eye Disease
|
Phase 3 | |
Completed |
NCT06159569 -
Performance and Tolerability of the Medical Device LACRIACT
|
N/A | |
Completed |
NCT05102409 -
An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease
|
Phase 2 | |
Completed |
NCT04081610 -
Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution
|
Phase 1 | |
Completed |
NCT05062564 -
Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye
|
N/A | |
Completed |
NCT05825599 -
PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms
|
N/A | |
Completed |
NCT03418727 -
Dry Eye Disease Study With Brimonidine
|
Phase 2 | |
Active, not recruiting |
NCT04425551 -
Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction
|
N/A | |
Recruiting |
NCT04527887 -
Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)
|
Phase 4 | |
Not yet recruiting |
NCT06379685 -
Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.
|
Phase 1 | |
Active, not recruiting |
NCT05618730 -
Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B
|
Phase 1 | |
Completed |
NCT04553432 -
Dry Eye OmniLenz Application of Omnigen Research Study
|
Phase 4 | |
Recruiting |
NCT04109170 -
Dry Eye Evaluation System Based on Bioinformatics
|
||
Completed |
NCT04105842 -
Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type
|
N/A | |
Completed |
NCT05505292 -
Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers
|
Phase 4 | |
Completed |
NCT04668131 -
Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease
|
N/A | |
Completed |
NCT06176651 -
Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers
|
Phase 4 | |
Not yet recruiting |
NCT02218827 -
Topical Steroid Treatment For Dry Eye
|
N/A | |
Completed |
NCT02235259 -
Efficacy and Safety of XG-104 for the Treatment of Dry Eye
|
Phase 2 | |
Completed |
NCT01959854 -
Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye
|
N/A |